Abstract: The invention relates to novel therapeutic approaches to cancer treatment that exploits tumor suppressor functions of DKK3b by site-specific delivery of DKK3b. Novel therapeutics and methods for treating tumors and cancers utilizing DKK3b tumor suppressor functions are disclosed.
Type:
Grant
Filed:
October 10, 2014
Date of Patent:
January 2, 2018
Assignee:
University of Massachusetts
Inventors:
Jack L. Leonard, Deborah M. Leonard, Karl J. Simin
Abstract: Trichome specific plant promoters are provided herein. Also provided are transgenic cells and organisms, especially plant cell and plants, comprising such trichome-specific promoter or a chimeric or vector comprising such trichome-specific promoter. The invention further provides methods for expressing nucleic acid sequences in cells and organisms using trichome specific promoters.
Type:
Grant
Filed:
November 29, 2013
Date of Patent:
January 2, 2018
Assignee:
Keygene N.V.
Inventors:
Paul Johan Diergaarde, Marinus Willem Prins, Martin De Vos
Abstract: The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide.
Type:
Grant
Filed:
October 14, 2015
Date of Patent:
December 19, 2017
Assignee:
BioMarin Pharmaceurical Inc.
Inventors:
Mika Aoyagi-Scharber, Teresa Margaret Christianson, Melita Dvorak-Ewell, Daniel J. Wendt, Shinong Long, Jonathan LeBowitz, Daniel Solomon Gold
Abstract: A method of treating a cardiomyopathy in a subject includes administering directly to or expressing locally in a weakened, ischemic, and/or peri-infarct region of myocardial tissue of the subject an amount of SDF-1 effective to cause functional improvement in at least one of the following parameters: left ventricular volume, left ventricular area, left ventricular dimension, cardiac function, 6-minute walk test, or New York Heart Association (NYHA) functional classification.
Type:
Grant
Filed:
December 9, 2013
Date of Patent:
December 19, 2017
Assignees:
The Cleveland Clinic, Juventas Therapeutics, Inc.
Inventors:
Marc S. Penn, Rahul Aras, Joseph Pastore, Timothy J. Miller
Abstract: The present invention provides anti-TNF? antibodies which selectively inhibit TNF? signalling through the p55R. In particular the present invention provides anti-TNF? antibodies which selectively inhibit TNF? signalling through the p55R relative to the p75R.
Type:
Grant
Filed:
November 24, 2005
Date of Patent:
December 12, 2017
Assignee:
UCB BIOPHARMA SPRL
Inventors:
Derek Thomas Brown, Hishani Kirby, Helene Margaret Finney, Alastair David Griffiths Lawson
Abstract: The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide.
Type:
Grant
Filed:
October 14, 2015
Date of Patent:
December 5, 2017
Assignee:
BIOMARIN PHARMACEUTICAL INC.
Inventors:
Mika Aoyagi-Scharber, Teresa Margaret Christianson, Melita Dvorak-Ewell, Daniel J. Wendt, Shinong Long, Jonathan LeBowitz, Daniel Solomon Gold
Abstract: Transposon nucleic acids comprising a transposon end sequence and a calibration sequence for DNA sequencing in the transposon end sequence. In one embodiment, the transposon end sequence is a Mu transposon end. A method for the generation of DNA fragmentation library based on a transposition reaction in the presence of a transposon end with the calibration sequence providing facilitated downstream handling of the produced DNA fragments, e.g., in the generation of sequencing templates.
Type:
Grant
Filed:
August 26, 2015
Date of Patent:
December 5, 2017
Assignee:
THERMO FISHER SCIENTIFIC OY
Inventors:
Ian Kavanagh, Laura-Leena Kiiskinen, Heli Haakana
Abstract: The screening method of the present invention is useful for screening drugs such as insulin secretagogues having an insulin secretagogue activity with minimized side effects (hypoglycemia induction, etc.). The transformant in which a polynucleotide encoding the fusion protein used for the screening method is introduced, the screening kit comprising the transformant, etc. are also useful for screening excellent drugs.
Abstract: Provided are isolated polynucleotides, polypeptides encoded thereby, nucleic acid constructs comprising same, plant cells and plants comprising same and methods of generating plants with increased yield, biomass, growth rate, vigor, oil content, fiber yield, fiber quality, abiotic stress tolerance, and/or nitrogen use efficiency, wherein the polynucleotides encode polypeptides at least 80% identical to SEQ ID NO: 574-930, 6266-10549 or 10550, such as the polynucleotides set forth in SEQ ID NOs:1-573, and 931-6265.
Abstract: The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide.
Type:
Grant
Filed:
October 14, 2015
Date of Patent:
December 5, 2017
Assignee:
BIOMARIN PHARMACEUTICAL INC.
Inventors:
Mika Aoyagi-Scharber, Teresa Margaret Christianson, Melita Dvorak-Ewell, Daniel J. Wendt, Shinong Long, Jonathan LeBowitz, Daniel Solomon Gold
Abstract: The invention relates to a chimeric protein comprising or consisting of, from N-terminal to C-terminal, (a) a N-terminal part of a Bordetella CyaA protein (b) a heterologous polypeptide comprising antigens originating from different HPVs, and (c) a C-terminal part of a Bordetella CyaA protein. The invention also relates to a polynucleotide encoding this chimeric protein. A composition comprising at least one chimeric protein(s) of the invention and the prophylactic and/or therapeutic uses of said composition are also part of the invention.
Type:
Grant
Filed:
July 23, 2013
Date of Patent:
November 28, 2017
Assignee:
GENTICEL
Inventors:
Yolande Misseri, Philippe Bridonneau, Anne Goubier
Abstract: The present invention provides compositions and methods for light-activated cation channel proteins and their uses within cell membranes and subcellular regions. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-activated cation channels to specific cells or defined cell populations. In particular the invention provides millisecond-timescale temporal control of cation channels using moderate light intensities in cells, cell lines, transgenic animals, and humans. The invention provides for optically generating electrical spikes in nerve cells and other excitable cells useful for driving neuronal networks, drug screening, and therapy.
Type:
Grant
Filed:
August 10, 2015
Date of Patent:
November 28, 2017
Assignee:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Abstract: Described are MMP8 inactivating antigen binding proteins, such as antigen binding proteins comprising an amino acid sequence that comprises 4 framework regions and 3 complementary determining regions; further described is the use of such antigen binding proteins to treat inflammation, such as, but not limited to, systemic inflammatory response syndrome, sepsis, LPS induced inflammation, renal ischemia/reperfusion injury, ventilation induced lung injury, periodontal inflammation, rheumatoid arthritis, multiple sclerosis, ankylosing spondylitis, Lyme arthritis and osteoarthritis.
Type:
Grant
Filed:
November 2, 2011
Date of Patent:
November 28, 2017
Assignees:
VIB vzw, Universiteit Gent
Inventors:
Claude Libert, Eline Dejonckheere, Roosmarijn Vandenbroucke
Abstract: The present invention relates to amino acid sequences that are directed against proteins from the group of the Angiopoietin/Tie family such as Tie1, Tie2, Ang1, Ang2, Ang3, Ang4, Angptl1, Angptl2, Angptl3, Angptl4, Angptl5, Angptl6, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more of such amino acid sequences.
Type:
Grant
Filed:
May 18, 2016
Date of Patent:
November 21, 2017
Assignee:
Ablynx N.V.
Inventors:
Maria Gonzalez Pajuelo, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Peter Vanlandschoot
Abstract: The present invention relates to an antibody-linker-drug conjugate in which an antibody and a cytotoxic drug are conjugated through an enzyme cleavable peptide linker capable of directly binding to a lysine residue of an antibody, a preparation method therefor, and an anticancer drug composition containing the same as an active ingredient.
Type:
Grant
Filed:
January 2, 2014
Date of Patent:
November 14, 2017
Assignee:
CELLTRION, INC.
Inventors:
Young Jun Park, Jin-kyo Jeong, Young Mi Choi, Minseob Lee, Yeon Jung Kim, Kyoung Suk Kim, Joon hun Choi, Jin Seo Lee, Eun Joo Cho, Hyunnam Song, Sung Jun Park, Jong-hyoup Lee, Matthew Sangyup Lee, In-Suk Lee, Joon woo Kim, Seung Suh Hong
Abstract: The present invention relates to ophthalmic and non-ophthalmic systems with blue light filtering and Yellowness Index ranges. UV and IR filtering are also included. Industrial applications are also outlined in the invention.
Type:
Grant
Filed:
September 25, 2014
Date of Patent:
November 14, 2017
Assignee:
High Performance Optics, Inc.
Inventors:
Andrew W. Ishak, Sean P. McGinnis, Ronald D. Blum, Michael B. Packard
Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.
Type:
Grant
Filed:
February 16, 2016
Date of Patent:
November 7, 2017
Assignee:
ACCLERON PHARMA INC.
Inventors:
Ravindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves
Abstract: Methods of producing biological materials from cells and organisms are provided. Aspects of the methods include modulating the stress conditions of the cells and/or organism to produce biological materials having one or more desired properties. In certain aspects, the cell or organism is evaluated to detect the presence or absence of a stressed phenotype, wherein an unstressed phenotype may be produced before the cell or organism produces the biological material of interest. The biological materials produced from such cells and organisms may be used for a variety of applications, including therapeutic, research, and other applications.
Abstract: The present invention relates to enzymes capable of hydrolysing organophosphate (OP) molecules. In particular, the invention relates to variants of the OpdA enzyme from Agrobacterium that display improved activity when compared to the naturally occurring OpdA. The invention is also towards polypeptides that have organophosphate hydrolysing activity for the organophosphates chlorpyrifos methyl, diazinon and parathion ethyl.
Type:
Grant
Filed:
July 20, 2012
Date of Patent:
October 24, 2017
Assignee:
COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION
Inventors:
Colin Scott, John Oakeshott, Robyn Russell, Nigel French, Steven Kotsonis, Kaiyan Liu
Abstract: There is provided an information processing apparatus including a determination unit configured to determine whether a user is consuming food and drink or whether food and drink is present in a periphery of the user, and a control unit configured to carry out control to output a control signal to an adding unit that adds a lighting effect to one of the food and drink present in a real space and picked-up images of the food and drink in accordance with a determination result of the determination unit.
Abstract: This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided.
Type:
Grant
Filed:
July 22, 2014
Date of Patent:
October 24, 2017
Assignee:
The Scripps Research Institute
Inventors:
Alexander Deiters, T. Ashton Cropp, Jason W. Chin, J. Christopher Anderson, Peter G. Schultz
Abstract: The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and/of impairment.
Type:
Grant
Filed:
July 16, 2015
Date of Patent:
October 24, 2017
Assignee:
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
Inventors:
Meredith Hay, John Konhilas, Robin L. Polt, Evan Jones
Abstract: The present invention relates to nucleic acid fragments and constructs comprising genomic nucleotide sequences, which are present upstream of Rb1 and p15C that are associated with intergenic transcription, for the production of a gene product of interest in a eukaryotic, preferably mammalian, host cell in the presence of a stringent selectable marker. The invention further relates to host cells comprising the nucleic acid constructs, to methods for generating the host cells and to methods for producing a gene product of interest using the host cells.
Type:
Grant
Filed:
June 15, 2011
Date of Patent:
October 17, 2017
Assignee:
CellaGenics B.V.
Inventors:
Arie Pieter Otte, Michel Siep, John Antonius Verhees, Femke Hoeksema, Henricus Johannes Maria Van Blokland
Abstract: A method includes determining a plurality of social objects, each social object having a link to a link object on a network. The method further includes applying a filter to the determined social objects in order to determine a plurality of filtered social objects, retrieving a copy of each of the link objects linked to by the plurality of filtered social objects, and generating, using the retrieved copies of the link objects linked to by the plurality of filtered social objects, a matrix comprising a plurality of vectors. The method further includes generating a singular value representation of the matrix by performing Singular Value Decomposition (SVD) on the matrix and storing the singular value representation of the matrix in one or more memory units.
Type:
Grant
Filed:
November 23, 2015
Date of Patent:
October 17, 2017
Assignee:
Brainspace Corporation
Inventors:
Paul A. Jakubik, David Adam Hagar, David S. Copps
Abstract: The present invention relates to expression vectors for the heterologous expression of a nucleic acid sequence of interest in mammalian cells, the vectors comprising a chimeric promoter regulatory sequence being operably linked to a nucleic acid sequence to be expressed, wherein the chimeric promoter regulatory sequence comprises a cytomegalovirus promoter sequence derived from murine cytomegalovirus or from human cytomegalovirus and being operably linked to the transcriptional start site of the nucleic acid sequence to be expressed; and a cytomegalovirus upstream region and/or enhancer sequence derived from human and/or the simian cytomegalovirus, wherein the upstream region and/or enhancer sequence is located 5? of and operably linked to the murine or the human promoter sequence, and wherein the chimeric promoter regulatory sequence comprises sequence elements being derived from at least two of the group consisting of murine cytomegalovirus, human cytomegalovirus and simian cytomegalovirus.
Abstract: Chemical mechanical polishing composition is provided. The composition comprises (A) inorganic particles, organic particles, or a mixture or composite thereof, (B) a protein, and (C) an aqueous medium.
Type:
Grant
Filed:
January 25, 2013
Date of Patent:
October 3, 2017
Assignee:
BASF SE
Inventors:
Yuzhuo Li, Bastian Marten Noller, Michael Lauter, Roland Lange
Abstract: A protein complex including at least two monoclonal antibodies is provided. By using the protein complex, a system for simultaneously targeting at least two antigens is effectively constructed.
Abstract: Provided are isolated polypeptides having beta-glucosidase activity and polynucleotides encoding the polypeptides. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
Type:
Grant
Filed:
December 19, 2012
Date of Patent:
September 26, 2017
Assignee:
Novozymes, Inc.
Inventors:
Ye Liu, Junxin Duan, Yu Zhang, Lan Tang
Abstract: The present invention relates in general to therapeutic fusion proteins useful to treat lysosomal storage diseases and methods for treating such diseases. Exemplary therapeutic fusion proteins comprise a lysosomal enzyme, a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide. Also provided are compositions and methods for treating Mucopolysaccharidosis Type IIIB (Sanfilippo B Syndrome), comprising a targeted therapeutic fusion protein comprising alpha-N-acetylglucosaminidase (Naglu), a lysosomal targeting moiety, e.g., an IGF-II peptide, and a spacer peptide.
Type:
Grant
Filed:
October 14, 2015
Date of Patent:
September 26, 2017
Assignee:
BioMarin Pharmaceutical Inc.
Inventors:
Mika Aoyagi-Scharber, Teresa Margaret Christianson, Melita Dvorak-Ewell, Daniel J. Wendt, Shinong Long, Jonathan LeBowitz, Daniel Solomon Gold
Abstract: Novel promoters which are derived from P. pastoris pastoris which are inducible or repressible under specific growth conditions are provided. These promoters are useful for regulating the expression of a desired structural gene, e.g., a mammalian polypeptide. Particularly preferred is the use of these novel promoters to regulate gene expression in polyploidal yeast such as diploidal P. pastoris produced by mating or spheroplast fusion.
Abstract: Compositions and methods are provided for the introduction and the regulated expression of genes in plants. Compositions include promoter constructs that provide a level of activity useful for the regulated expression of site-specific recombinases, while avoiding premature excision. Further provided are isolated polynucleotides encoding novel babyboom polypeptides, expression cassettes, and plants comprising the same. Methods for the introduction of genes into plants are provided, including methods for plastid transformation and methods for the transformation of tissues from mature seeds and leaves.
Type:
Grant
Filed:
November 22, 2013
Date of Patent:
September 19, 2017
Assignees:
E I DU PONT DE NEMOURS AND COMPANY, PIONEER HI-BRED INTERNATIONAL, INC.
Inventors:
William James Gordon-Kamm, Theodore Mitchell Klein, Keith S Lowe, Kevin E McBride, Christopher Jay Scelonge, Ning Wang
Abstract: Provided is a method of inhibiting heterodimerization of HIF-2? to HIF1? (ARNT) comprising binding certain small molecules to the HIF-2? PAS-B domain cavity but not to HIF1? and inhibiting HIF-2? heterodimerization to HIF1? (ARNT) but not inhibiting HIF1? heterodimerization to HIF1? (ARNT). Those certain small molecules are also referenced synonymously as HIF2-HDI and HIF2? heterodimerization inhibitors and also simply as certain small molecules.
Type:
Grant
Filed:
November 14, 2013
Date of Patent:
September 12, 2017
Assignee:
The Board of Regents of the University of Texas System
Inventors:
Richard K. Bruick, Charles G. Caldwell, Doug E. Frantz, Kevin H. Gardner, John B. MacMillan, Thomas H. Scheuermann, Uttam K. Tambar
Abstract: The present invention relates to epitope peptides (or mutants thereof) for treating hepatitis B virus infection, recombinant proteins comprising such epitope peptides (or mutants thereof) and carrier proteins, and uses of such epitope peptides (or mutants thereof) and recombinant proteins. The present invention also relates to antibodies against such epitope peptides, cell lines producing said antibodies, and uses thereof. Furthermore, the present invention relates to vaccines or pharmaceutical compositions for treating or alleviating one or more symptoms associated with hepatitis B virus infection, which comprise the recombinant proteins or antibodies according to the invention, respectively.
Abstract: Nucleic acid molecules which encode an MRSA PBP2a protein or a fragment thereof which comprises at least 245 amino acid are disclosed. Compositions comprising the nucleic acid molecules are disclosed. Novel proteins which comprise a MRSA PBP2a protein or a fragment thereof which comprises at least 245 amino acid are disclosed are disclosed. Methods of inducing an immune response against MRSA PBP2a are disclosed, as are methods of treating an individual who has been diagnosed with MRSA and methods of preventing MRSA infection in an individual.
Type:
Grant
Filed:
December 11, 2012
Date of Patent:
September 5, 2017
Assignee:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Abstract: The present inventors obtained, from a phage library of human antibodies, an anti-mouse NR 10 neutralizing antibody-expressing BM095 clone that shows a strong proliferation-suppressing activity in an IL-31-dependent Ba/F3 cell proliferation assay system. When this anti-mouse NR 10 neutralizing antibody was administered to NC/Nga mice, a model of atopic dermatitis which is a mouse model of chronic dermatitis that arises as a result of repeated applications of picryl chloride, a mouse model of rheumatoid arthritis, and a mouse model of osteoarthritis, a significant effect of symptom suppression was observed. This revealed that the anti-NR 10 neutralizing antibody is indeed effective as a therapeutic agent for inflammatory diseases. In addition, the present inventors successfully obtained an anti-human NR 10 neutralizing antibody, providing extremely useful therapeutic agents with practical clinical applications.
Abstract: The present invention provides combinations of specific binding proteins, such as immunoglobulins, that are designed to be true combinations, essentially all components of the combination being functional and compatible with each other. The invention further provides a method for producing a composition comprising at least two different proteinaceous molecules comprising paired variable regions, the at least two proteinaceous molecules having different binding specificities, comprising paired variable regions, at least two proteinaceous molecules having different binding specificities, comprising contacting at least three different variable regions under conditions allowing for pairing of variable regions and harvesting essentially all proteinaceous molecules having binding specificities resulting from the pairing.
Type:
Grant
Filed:
February 14, 2011
Date of Patent:
August 22, 2017
Assignee:
Merus N.V.
Inventors:
Hendricus Renerus Hoogenboom, Ton Logtenberg
Abstract: This invention relates to novel rationale and methods for identifying human and primate taste-specific genes, including genes involved in salty taste perception, especially human salty taste perception, but also genes involved in sweet, bitter, umami, and sour taste perception, and genes involved in other taste cell or taste receptor related activities such as digestive function and digestive related diseases, taste cell turnover, immunoregulation of the oral and digestive tract, and metabolic regulation such as in diabetes and obesity, the genes identified using these methods, and assays for identifying taste modulators (enhancers or blockers) and potential therapeutics using these genes. These compounds have potential application in modulating (enhancing or blocking) taste perception, especially salty taste perception and as potential therapeutics.
Type:
Grant
Filed:
August 12, 2015
Date of Patent:
August 22, 2017
Assignee:
SENOMYX, INC.
Inventors:
Bryan Moyer, Albert Zlotnik, Peter Hevezi, Hortensia Soto, Dalia Kalabat, Min Lu, Na Gao, Evan Carl White
Abstract: There is provided inter alia a process for stabilizing a eukaryotic cell line which expresses PylRS and tRNAPyl and which is suitable for incorporation of a gene encoding a target protein containing one or more non-natural amino acids encoded by a nonsense codon which comprises culturing said cell line under conditions in which the adverse effect of tRNAPyl expression on cell viability and/or cell growth is reduced or eliminated.
Type:
Grant
Filed:
September 24, 2013
Date of Patent:
August 15, 2017
Assignee:
MEDIMMUNE LIMITED
Inventors:
Kenneth H. Grabstein, Michael Van Brunt, Marcello Marelli, William Brady, Jeffrey C. Johnson
Abstract: Disclosed herein are compositions and methods for treating Clostridium botulinum neurotoxin intoxication and in particular, vaccines against the neurotoxin that provide protection again lethal challenge with neurotoxin from one or more serotypes of Clostridium botulinum.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
August 15, 2017
Assignee:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Inventors:
David B. Weiner, Veronica Scott, Natalie Hutnick
Abstract: General methods and strains of bacteria are described that dramatically simplify and streamline plasmid DNA production. In one preferred embodiment, endolysin mediated plasmid extraction combined with flocculation mediated removal of cell debris and host nucleic acids achieves increased yield and purity with simplified downstream purification and reduced waste streams, thus reducing production costs.
Type:
Grant
Filed:
February 3, 2015
Date of Patent:
August 8, 2017
Assignee:
Nature Technology Corporation
Inventors:
James A. Williams, Clague P. Hodgson, Aaron E. Carnes
Abstract: The present invention provides a novel method for the recombinant production of Factor C protein from horseshoe crab using a parasitic protozoan expressing the Factor C protein. In particular, the present invention provides a parasitic protozoan host cell harboring a polynucleotide encoding horseshoe crab Factor C protein, and a method for producing Factor C protein comprising culturing said parasitic protozoan host cell under conditions such that the cells express the horseshoe crab Factor C protein. Furthermore, the present invention provides recombinant Factor C protein produced by the novel method and its use in the detection and/or removal of endotoxin.
Abstract: The present disclosure provides synthetic collagen and methods of making and using synthetic collagen that include a synthetic collagen that facilitates wound closure comprising an isolated and purified triple helical backbone protein that facilitates wound closure comprising one or more alteration in a triple helical backbone protein sequence, that stabilize the isolated and purified triple helical backbone protein and does not disrupt an additional collagen ligand interaction; and one or more integrin binding motifs, wherein the isolated and purified triple helical backbone protein facilitates wound closure.
Type:
Grant
Filed:
December 3, 2013
Date of Patent:
August 8, 2017
Assignee:
THE TEXAS A&M UNIVERSITY SYSTEM
Inventors:
Brooke H. Russell, Magnus Hook, Mariah S. Hahn, Elizabeth M. Cosgriff-Hernandez, Neungseon Seo, Marvin Xuejun Xu, Jose J. Rivera, Mary Beth Browning
Abstract: The present invention relates to a method and apparatus for the isolation, modification and re-administration of a molecule or biomolecule, or a class of biomolecules, from the body fluid of a mammal via an extracorporeal closed circuit device. The device is able to capture and modify the biomolecule by the covalent or non-covalent attachment of a secondary molecule or protein, by cross-linking the captured molecule, or by altering the structure of the molecule (for example, by deglycosylation, peptide cleavage, or aggregation). The apparatus can be used to return the modified molecule or biomolecule to the mammalian subject. The device and methods may be utilized for the patient-specific diagnosis and/or treatment of a disease state which presents an associated molecule or protein in plasma or any other fluidized physiological system.
Abstract: The present disclosure relates to hemojuvelin-IgG Fc domain fusion proteins, variants, derivatives, fragments and peptide mimetics derived therefrom and methods of using these fusion proteins for the regulation of iron homeostasis and the treatment of diseases related to iron homeostasis.
Type:
Grant
Filed:
January 19, 2012
Date of Patent:
July 18, 2017
Assignees:
THE GENERAL HOSPITAL CORPORATION, FERRUMAX CORPORATION
Inventors:
Herbert Y. Lin, Jodie L. Babitt, Tracey Menhall, Patrick Gearing
Abstract: Disclosed are novel compositions and methods for introduction of macromolecules and nanoparticles into living cells. The invention includes a polypeptide sequence which when fused to a macromolecule or nanoparticle enhances its introduction into the cell.
Type:
Grant
Filed:
March 30, 2012
Date of Patent:
July 11, 2017
Assignee:
The Regents of the University of Colorado, a body corporate
Abstract: This invention relates to phytases, polynucleotides encoding them, uses of the polynucleotides and polypeptides of the invention, as well as the production and isolation of such polynucleotides and polypeptides. In particular, the invention provides polypeptides having phytase activity under high temperature conditions, and phytases that retain activity after exposure to high temperatures. The invention further provides phytases which have increased gastric lability. The phytases of the invention can be used in foodstuffs to improve the feeding value of phytate rich ingredients. The phytases of the invention can be formulated as foods or feeds or supplements for either to, e.g., aid in the digestion of phytate.
Type:
Grant
Filed:
May 20, 2010
Date of Patent:
July 4, 2017
Assignee:
Syngenta Participations AG
Inventors:
David P. Weiner, Arne I. Solbak, Jr., Ryan McCann
Abstract: Methods for demannosylating phosphorylated N-glycans on a glycoprotein are described that use a mannosidase capable of hydrolyzing a terminal alpha-1,2 mannose linkage when the underlying mannose is phosphorylated.
Type:
Grant
Filed:
September 29, 2011
Date of Patent:
June 27, 2017
Assignee:
Oxyrane UK Limited
Inventors:
Kathleen Camilla Telesphore Alida Maria Piens, Wouter Vervecken
Abstract: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.
Type:
Grant
Filed:
January 5, 2015
Date of Patent:
June 27, 2017
Assignee:
Wyeth LLC
Inventors:
Stephen Berasi, Robert Vincent Martinez, Michael John Cain, John Martin Wozney, Howard Joel Seeherman, Zong Sean Juo, Valerie Perrine Calabro, Christopher Todd Brown